Navigation Links
Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting
Date:12/2/2009

ution or improvement of the bullous reaction.

Clinical cases of hypothyroidism have been reported in thyroidectomy patients undergoing levothyroxine replacement during treatment with Gleevec. TSH levels should be closely monitored in such patients.

Consider potential toxicities--specifically liver, kidney, and cardiac toxicity, and immunosuppression from long-term use.

Fetal harm can occur when administered to a pregnant woman; therefore, women of childbearing potential should be advised to not become pregnant while taking Gleevec tablets and to avoid breast-feeding while taking Gleevec tablets because of the potential for serious adverse reactions in nursing infants. Sexually active female patients taking Gleevec should use adequate contraception. If the patient does become pregnant while taking Gleevec, the patient should be advised of the potential hazard to the fetus.

Gleevec is metabolized by the CYP3A4 isoenzyme and is an inhibitor of CYP3A4, CYP2D6, and CYP2C9. Dosage of Gleevec should increase by at least 50%, and clinical response should be carefully monitored, in patients receiving Gleevec with a potent CYP3A4 inducer such as rifampin or phenytoin. Examples of commonly used drugs that may significantly interact with Gleevec include ketoconazole, acetaminophen, warfarin, erythromycin, and phenytoin. (Please see full Prescribing Information for other potential drug interactions.)

For daily dosing of 800 mg and above, dosing should be accomplished using the 400-mg tablet to reduce exposure to iron.

Common side effects of Gleevec tablets

The majority of adult patients with Ph+ CML who received Gleevec in clinical studies experienced adverse reactions at some time, but most were mild to moderate in severity. The most frequently reported adverse reactions (all Grades) were superficial edema (60%-74%), nausea (50%-73%), diarrhea (43%-57%), musculoskeletal pain (38%-49%), rash an
'/>"/>

SOURCE Novartis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
4. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
5. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
6. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study
10. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
11. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ... the Jefferies 2014 Boston Healthcare Summit next week in ... on August 6, 2014 and will not be webcast. ... BioPharma manages a portfolio of patents and royalty assets, ... patents and license agreements with various biotechnology and pharmaceutical ...
(Date:7/30/2014)... Die Apex Medical Corporation (Apex, ... Atemtherapie- und Druckzonenprodukte, gibt bekannt, dass sie ... anfechten werden. Dieses hat entschieden, dass die ... ResMed verletze. Apex weist darauf hin, dass ... Patente von ResMed Anfechtungen wegen Nichtigkeit eingeleitet ...
(Date:7/29/2014)... 29, 2014 /PRNewswire-iReach/ -- The global microbial identification ... methods, applications, end users, and geographies. Genotypic technology ... microbial identification market. This favorable growth is attributed ... and the time required for microbial identification along ... Furthermore, genotypic methods have high applications in clinical ...
Breaking Medicine Technology:PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6
... , TAMPA, Fla. , April 26 ... today that Zirgan™ (ganciclovir ophthalmic gel) 0.15% is now commercially ... Drug Administration in September 2009 , is a topical ... (dendritic ulcers).   , ...
... April 26 Aton Pharma, Inc., a ... acquired the U.S. marketing rights to LODOSYN® (carbidopa) tablets ... use with carbidopa-levodopa or with levodopa in the treatment ... administration of lower doses of levodopa with reduced nausea ...
Cached Medicine Technology:Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 2Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 3Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa) 2Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa) 3Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa) 4
(Date:7/30/2014)... ... ... ... , UCLA researchers interviewed people with diverticulitis and confirmed that many suffer psychological and physical symptoms long after their ... UCLA team led by Dr. Brennan Spiegel interviewed patients in great detail about the symptoms they experience weeks, months or even years ...
(Date:7/30/2014)... The Ehlers-Danlos National Foundation (EDNF) is pleased to ... will serve as chair. The board was voted upon ... Conference in Houston, Texas July 10-12. , “The ... us. From the rollout of the first EDNF Center ... Medical Center to our September physicians conference to a ...
(Date:7/30/2014)... OR (PRWEB) July 30, 2014 LTC Consumer, ... evaluate long term care insurance, features an Instant Quote tool ... Director and co-founder of LTC Consumer. Quotes are free and ... a click in only seven areas – including age, gender, ... on screen within seconds (you don’t need to enter any ...
(Date:7/30/2014)... The American Telemedicine Association (ATA) today ... (R-MS) and Roger Wicker (R-MS) for their efforts ... Medicare, Medicaid and Federal Communications Commission programs. , ... the Telehealth Enhancement Act as S. 2662, a ... introduced by Rep. Gregg Harper (R-MS) which already ...
(Date:7/30/2014)... July 30, 2014 Hospitals continually ... quality of care that their practitioners provide. During ... Andrew Rowe, discussed the importance of establishing effective ... physician performance and quality of care. , ... evaluation, Mr. Rowe elaborated on setting performance expectations, ...
Breaking Medicine News(10 mins):Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3Health News:Ehlers-Danlos National Foundation Announces New Leadership 2Health News:LTC Consumer Launches Online Tool for Getting Instant Long Term Care Insurance Estimates 2Health News:ATA Applauds Senators’ Push for Federal Telemedicine Improvements 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 3
... risk factors are known to play a role in the ... known about the effect of body mass index and clustering ... ,Recently a study, published in the October issue of ... the relation between midlife body mass index and clustering of ...
... dysfunction (ED) is the inability of a man to achieve ... the needs of his partner. Most men experience this at ... are not psychologically affected by it. Some men, however, experience ... ,According to a new study in the October ...
... HIV vaccine is being jointly developed by Vical Pharmaceuticals and ... was developed by the scientistis in NIH and the Federal ... inserting the HIV genes//. ,Vical Inc. is a ... DNA delivery system, last month Vical has agreed to grant ...
... has been set up in Pakistani Kashmir to provide surgery ... ,The hospital was erected in just 2 hours//. The unit ... paramedical staff. The mobile unit was transported to Muzaffarabad, the ... medical facility has proved to be a boon to the ...
... up lately and this is causing harm to the patients ... tests, says a new study that was published online today ... of the University of Pittsburgh and colleagues studied 24,000 cases ... that erroneous diagnosis was made in nearly 1,300 cases. The ...
... is the most common cause of chronic liver disease ... NAFLD is currently available//. Understanding the specific effects of ... is important for patient counseling as well as for ... these issues, researchers from Mayo Clinic College of Medicine, ...
Cached Medicine News:Health News:Erectile dysfunction: an early warning sign of clinically silent coronary artery disease? 2Health News:Weight reduction by 5% may help in treating nonalcoholic fatty liver disease 2
... 20-year history, the VOYAGER RX Dilatation Catheter ... outcomes. It combines a new low profile, ... shaft,more flexible markers, and short taper balloon ... tortuous anatomy with even greater confidence, opening ...
... technology developed over Guidants 20-year history, the ... foundation for successful treatment outcomes. It combines ... with a lower profile shaft,more flexible markers, ... can cross tight and tortuous anatomy with ...
... Coat-A-Count AFP IRMA,is an ... measurement of,alpha-fetoprotein (AFP) in serum. ... vitro use in either of,two ... aid in the,management of patients ...
Enzyme immunoassay for the quantitative determination of ovarian cancer antigen CA125 in human serum...
Medicine Products: